Novavax Inc expects to produce up to 150 million COVID-19 vaccine doses monthly by May or June, its chief executive told Reuters on Friday, a day after reporting interim data that showed its shot to be 89% effective in a UK trial.
Novavax expects to complete the clinical trial for its experimental COVID-19 vaccine in the next few weeks, but is already working on manufacturing to be able to reach full production capacity quickly, Chief Executive Officer Stanley Erck said.
“We should be at full capacity starting in May or June, maybe as much as one hundred and fifty million doses per month globally,” he said.
Erck said he expects it will be several weeks before Novavax files the trial data with regulators in the United Kingdom, Europe and elsewhere, meaning that full review for authorization of its vaccine could take “a couple months.”
